Literature DB >> 35802286

Icariin: A Potential Neuroprotective Agent in Alzheimer's Disease and Parkinson's Disease.

Mohammad Rafi Khezri1, Morteza Ghasemnejad-Berenji2,3.   

Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases worldwide. They are characterized by the loss of neurons and synapses in special parts of the central nervous system (CNS). There is no definitive treatment for AD and PD, but extensive studies are underway to identify the effective drugs which can slow the progression of these diseases by affecting the factors involved in their pathophysiology (i.e., aggregated proteins, neuroinflammation, and oxidative stress). Icariin, a natural compound isolated from Epimedii herba, is known because of its anti-inflammatory and anti-oxidant properties. In this regard, there are numerous studies indicating its potential as a natural compound against the progression of CNS disorders, such as neurodegenerative diseases. Therefore, this review aims to re-examine findings on the pharmacologic effects of icariin on factors involved in the pathophysiology of AD and PD.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; Icariin; Neuroinflammation; Oxidative stress; Parkinson’s disease

Mesh:

Substances:

Year:  2022        PMID: 35802286     DOI: 10.1007/s11064-022-03667-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   4.414


  66 in total

Review 1.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

2.  Pharmacokinetics and tissue distribution profile of icariin propylene glycol-liposome intraperitoneal injection in mice.

Authors:  Wei Yang; Xi-Chong Yu; Xing-Yan Chen; Lu Zhang; Cui-Tao Lu; Ying-Zheng Zhao
Journal:  J Pharm Pharmacol       Date:  2011-11-18       Impact factor: 3.765

3.  Metabolite profiles of icariin in rat plasma by ultra-fast liquid chromatography coupled to triple-quadrupole/time-of-flight mass spectrometry.

Authors:  Qian Qian; Song-Lin Li; E Sun; Ke-Rong Zhang; Xiao-Bin Tan; Ying-Jie Wei; Hong-Wei Fan; Li Cui; Xiao-Bin Jia
Journal:  J Pharm Biomed Anal       Date:  2012-04-05       Impact factor: 3.935

Review 4.  The Role of ERK1/2 Pathway in the Pathophysiology of Alzheimer's Disease: An Overview and Update on New Developments.

Authors:  Mohammad Rafi Khezri; Keyvan Yousefi; Ayda Esmaeili; Morteza Ghasemnejad-Berenji
Journal:  Cell Mol Neurobiol       Date:  2022-01-17       Impact factor: 5.046

5.  Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo).

Authors:  Yan Chen; Yan Hong Zhao; Xiao Bin Jia; Ming Hu
Journal:  Pharm Res       Date:  2008-05-06       Impact factor: 4.200

6.  Pharmacokinetics, Tissue Distribution, and Metabolism Study of Icariin in Rat.

Authors:  Shunjun Xu; Jiejing Yu; Jingjing Zhan; Liu Yang; Longgang Guo; Yijuan Xu
Journal:  Biomed Res Int       Date:  2017-11-13       Impact factor: 3.411

7.  Role of intestinal hydrolase in the absorption of prenylated flavonoids present in Yinyanghuo.

Authors:  Yan Chen; Jinyan Wang; Xiaobin Jia; Xiaobin Tan; Ming Hu
Journal:  Molecules       Date:  2011-02-01       Impact factor: 4.411

8.  Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity.

Authors:  Di-Sheng Lu; Ce Chen; Ya-Xin Zheng; Dai-Di Li; Guo-Qing Wang; Jie Liu; Jingshan Shi; Feng Zhang
Journal:  Front Mol Neurosci       Date:  2018-05-16       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.